Tetra Bio-Pharma’s Subsidiary, Panag Pharma, Obtains Health Canada Authorization to Commence Its First Veterinary Clinical Study
Panag Pharma Inc. today announced that its pilot clinical study to evaluate the tolerability and potential efficacy of its PPP003 ophthalmic drug in the treatment of indolent corneal ulcers in companion animals has been authorized by the Veterinary Drugs Directorate (VDD), Health Canada.